Polyphenols, including anthocyanins, flavonoids and stilbenes, which constitute one of the most abundant and ubiquitous groups of plant metabolites, are an integral part of the human diet. Resveratrol (3,5,4'-trihydroxystilbene), a naturally occurring polyphenol produced by some plants as a self-defence agent, has an antifungal activity. Resveratrol has been found in some plants (such as grapevine, pine and peanuts) and is considered to have beneficial effects also on human health. The number of studies on resveratrol greatly increased in PubMed database since 1997, after the anticancer effect of this molecule was first reported. The interest in resveratrol in grape was originally sparked by epidemiological studies indicating an inverse relationship between long-standing moderate consumption of red wine and the risk of coronary heart disease; this effect has been ascribed to resveratrol, which possesses diverse biochemical and physiological properties, including antiplatelet and anti-inflammatory proprieties, and provides a wide range of health benefits ranging from chemoprevention to cardioprotection. Recently, resveratrol has been described as an anti-aging compound. The consumption of resveratrol (red wine) together with a Mediterranean diet or a fast-food meal (“McDonald'sMeal”) had a positive impact on oxidized (ox-) LDL and on the expression of oxidative and inflammatory genes. Therefore, this review summarized the most important scientific data about healing and preventive potential of resveratrol, acting as cardioprotective, neuroprotective, chemopreventive and antioxidant agent.
TakaokaM. (1940) Phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). II. Synthesis of resveratrol and its derivatives. Proceedings of the Imperial Academy (Tokyo), 16, 405–407.
2.
LangcakeP., PryceR.J. (1976) The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiological Plant Pathology, 9, 77–86.
3.
TakayaY., YanK-X, TerashimaK., HeY-H, NiwaM. (2002) Biogenic reactions on stilbene tetramers from Vitaceaeous plants. Tetrahedron, 58, 9265–9271.
4.
CallemienD., CounetC., CawetQ., CollinS. (2003) Hop as a determinant nutrition key for health. Proceedings of the 29th European brewery convention congress, Fachverlag Hans Karl, Germany. 1375–1382.
5.
CounetC., CallemienD., CollinS. (2006) Chocolate and cocoa: New sources of trans-resveratrol and trans-piceid. Food Chemistry, 98, 649–657.
6.
ChungI.M., ParkM.R., ChunJ.C., YunS.J. (2003) Resveratrol accumulation and resveratrol synthase gene expression in response to abiotic stresses and hormones in peanut plants. Plant Science, 164, 103–109.
7.
AdrianM., JeandetP., Douillet-BreuilA.C., TessonL., BessisR. (2000) Stilbene content of mature Vitis vinefera berries in response to UV-C elicitation. Journal of Agricultural and Food Chemistry, 48, 6103–6105.
8.
VersariA., ParpinelloG.P., TornielliG.B., FerrariniR., GiulivoC. (2001) Stilbene compounds and stilbene synthase expression during ripening, wilting, and UV treatment in grape cv. Corvina. Journal of Agricultural and Food Chemistry, 49, 5531–5536.
9.
GrimmigB., Gonzalez-PerezM.N., WelzlG., PenuelasJ., SchubertR., HainR., HeidenreichB., BetzC., LangebartelsC., ErnstD., SandermannH.Jr.. (2002) Ethylene- and ozone-induced regulation of a grapevine resveratrol synthase gene: different responsive promoter regions. Plant Physiology and Biochemistry, 40, 865–870.
10.
JiménezB., OreaJ.M., UreñaA.G., EscribanoP., López de la OsaP., GuadarramaA. (2007) Short anoxic treatments to enhance trans-resveratrol content in grapes and wine. European Food Research and Technology, 224, 373–378.
GiorcelliA., SparvoliF., MattiviF., TavaA., BalestrazziA., VrhovsekU., CalligariP., BolliniR., ConfalonieriM. (2004) Expression of the stilbene synthase (StSy) gene from grapevine in transgenic white poplar results in high accumulation of the antioxidant resveratrol glucosides. Transgenic Research, 13, 203–214.
13.
HallsC., YuO. (2008) Potential for metabolic engineering of resveratrol biosynthesis. Trends in Biotechnology, 26, 77–81.
14.
DelaunoisB., CordelierS., ConreuxA., ClémentC., JeandetP. (2009) Molecular engineering of resveratrol in plants. Plant Biotechnology Journal, 7, 2–12.
15.
CreasyL.L., CoffeeM. (1988) Phytoalexin production potential of grape berries. Journal of the American Society for Horticultural Science, 113, 230–234.
16.
JeandetP., BessisR., GautheronB. (1991) The production of resveratrol (3,5,4'-trihydroxystilbene) by grape berries in different developmental stages. American Journal of Enology and Viticulture, 42, 41–46.
17.
LiX., WuB., WangL., LiS. (2006) Extractable amounts of trans-resveratrol in seed and berry skin in Vitis evaluated at the germplasm level. Journal of Agricultural and Food Chemistry, 54, 8804–8811.
18.
Romero-PérezA.I., Ibern-GómezM., Lamuela-RaventósR.M., de La Torre-BoronatM.C. (1999) Piceid, the major resveratrol derivative in grape juices. Journal of Agricultural and Food Chemistry, 47, 1533–1536.
19.
ColicaC., De LorenzoA., AbenavoliL. (2018) Mediterranean diet in liver steatosis: the role of polyphenols. Minerva Gastroenterologica e Dietologica, 64, 97–99.
20.
BaurJ.A., SinclairD.A. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews Drug Discovery, 5, 493–506.
21.
BorrielloA., CucciollaV., Della RagioneF., GallettiP. (2010) Dietary polyphenols: Focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis. Nutrition, Metabolism & Cardiovascular Diseases, 20, 618–625.
22.
GuerreroR.F., García-ParrillaM.C., PuertasB., Cantos-VillarE. (2009) Wine, Resveratrol and Health: a Review. Natural Product Communications, 4, 635–658.
23.
GrønbeakM. (2002) Alcohol, type of alcohol and all-cause and coronary heart disease mortality. Annals of the New York Academy of Sciences, 957, 16–20.
24.
JangM., CaiL., UdeaniG.O., SlowingK.V., ThomasC.F., BeecherC.W., FongH.H., FarnsworthN.R., KinghornA.D., MehtaR.G., MoonR.C., PezzutoJ.M. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218–220.
25.
AtharM., BackJ.H., TangX., KimK.H., KopelovichL., BickersD.R., KimA.L. (2007) Resveratrol: A review of preclinical studies for human cancer prevention. Toxicology and Applied Pharmacology, 224, 274–283.
26.
BelguendouzL., FremontL., LinardA. (1997) Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochemical Pharmacology, 53, 1347–1355.
27.
NilesR.M., CookC.P., MeadowsG.G., FuY.M., McLaughlinJ.L., RankinG.O. (2006) Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. Journal of Nutrition, 136, 2542–2546.
28.
RenaudS., De LorgerilM. (1992) Wine, alcohol, platelets and the French Paradox for coronary heart disease. Lancet, 339, 1523–1529.
29.
UngvariZ., OroszZ., LabinskyyN., RiveraA., XiangminZ., SmithK., CsiszarA. (2007) Increased mitochondrial H2O2 production promotes endothelial NF-κB activation in aged rat arteries. American Journal of Physiology-Heart and Circulatory Physiology, 293, H37–H47.
30.
UngvariZ., LabinskyyN., MukhopadhyayP., PintoJ.T., BagiZ., BallabhP., ZhangC., PacherP., CsiszarA. (2009) Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. American Journal of Physiology-Heart and Circulatory Physiology, 297, H1876–H1881.
31.
WangZ., HuangY., ZouJ., CaoK., XuY., WuJ.M. (2002) Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro.International Journal of Molecular Medicine, 9, 77–79.
32.
WenzelE., SoldoT., ErbersdoblerH., SomozaV. (2005) Bioactivity and metabolism of trans-resveratrol orally administrated to Wistar rats. Molecular Nutrition & Food Research, 49, 482–494.
33.
ZouJ.G., HuangY.Z., ChenQ., WeiE.H., HsiehT.C., WuJ.M. (1999) Resveratrol inhibits copper ion-induced and azo compound-initiated oxidative modification of human low density lipoprotein. Biochemistry and Molecular Biology International, 47, 1089–1096.
DiasK., NikolaouS. (2011) Does the combination of resveratrol with Al (III) and Zn (II) improve its antioxidant activity?Natural Product Communications, 6, 1673–1676.
37.
MozafariM., NekooeianA.A., MashghoolozekrE., PanjeshahinM.R. (2015) The cardioprotective effects of resveratrol in rats with simultaneous type 2 diabetes and renal hypertension. Natural Product Communications, 10, 335–338.
38.
LaneriS., SacchiA., FratterA., BertinW., BinoA., VertuaniS., ManfrediniS. (2017) Self-nanoemulsifying system in the accumulation of resveratrol and N-acetylcysteine in the epidermis and dermis. Natural Product Communications, 12, 1785–1787.
39.
MarkusM.A., MorrisB.J. (2008) Resveratrol in prevention and treatment of common clinical conditions of aging. Clinical Interventions in Aging, 3, 331–339.
40.
DasM., DasD.K. (2010) Resveratrol and cardiovascular health. Molecular aspects of Medicine, 31, 503–512.
41.
MurrayC.J., LopezA.D. (1997) Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet, 349, 1436–1442.
42.
CastelliW.P. (1998) The new pathophysiology of coronary artery disease. American Journal of Cardiology, 82, 60T–65T.
43.
AbeywardenaM.Y. (2003) Dietary fats, carbohydrates and vascular disease: Sri Lankan perspective. Atherosclerosis, 171, 157–161.
44.
NicholsonS.K., TuckerG.A., BrameldJ.M. (2008) Effects of dietary polyphenols on gene expression in human vascular endothelial cells. The Proceedings of the Nutrition Society, 67, 42–47.
45.
KinlayS., LibbyP., GanzP. (2001) Endothelial function and coronary artery disease. Current Opinion in Lipidology, 12, 383–389.
46.
DavingnonJ., GanzP. (2004) Role of endothelial dysfunction in atherosclerosis. Circulation, 109, III27–III32.
47.
RubboH., TrostchanskyA., BottiH., BatthyányC. (2002) Interaction of nitric oxide and peroxynitrite with low-density lipoprotein. Biological Chemistry, 383, 547–552.
AbenavoliL., MilicN., LuzzaF., BoccutoL., De LorenzoA. (2017) Polyphenols treatment in patients with nonalcoholic fatty liver disease. Journal of Translation Internal Medicine, 5, 144–147.
52.
LeightonF., CuevasA., GuaschV., PérezD.D., StrobelP., San MartínA., UrzuaU., DíezM.S., FonceaR., CastilloO., MizónC., EspinozaM.A., UrquiagaI., RozowskiJ., MaizA., GermainA. (1999) Plasma polyphenol and antioxidants, oxidative DNA damage and endothelial function in diet and wine intervention study in humans. Drugs Under Experimental and Clinical Research, 25, 133–141.
53.
BlannA.D., LipG.Y. (1998) The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagulation & Fibrinolysis, 9, 297–306.
54.
ShahA.M., ChannonK.M. (2004) Free radicals and redox signalling in cardiovascular disease. Heart, 90, 486–487.
55.
GriendlingK.K. (2006) NADPH oxidases: new regulators of old functions. Antioxidant Redox Signal, 8, 1443–1445.
ValerioA., CardileA., CozziV., BracaleR., TedescoL., PiscontiA., PalombaL., CantoniO., ClementiE., MoncadaS., CarrubaM.O., NisoliE. (2006) TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. Journal of Clinical Investigation, 116, 2791–2798.
58.
MaZ.H., MaQ.Y., ShaH.C., WangL.C. (2006) Effect of resveratrol on lipopolysaccharide-induced activation of rat peritoneal macrophages. Nan fang yi ke da xue xue bao, 26, 1363–1365.
59.
MarierJ.F., ChenK., PrinceP., ScottG., del CastilloJ.R., VachonP. (2005) Production of ex vivo lipopolysaccharide-induced tumor necrosis factor-alpha, interleukin-1beta, interleukin-6 is suppressed by trans-resveratrol in a concentration-dependent manner. Canadian Journal of Veterinary Research, 69, 151–154.
60.
ZhangH., ZhangJ., UngvariZ., ZhangC. (2009) Resveratrol improves endothelial function: role of TNF-α and vascular oxidative stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 1164–1171. 2009.
61.
UngvariZ., OroszZ., RiveraA., LabinskyyN., XiangminZ., OlsonS., PodlutskyA., CsiszarA. (2007) Resveratrol increases vascular oxidative stress resistance. American Journal of Physiology-Heart and Circulatory Physiology, 292, H2417–H2424.
62.
ChowH.H., GarlandL.L., HsuC.H., ViningD.R., ChewW.M., MillerJ.A., PerloffM., CrowellJ.A., AlbertsD.S. (2010) Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prevention Research, 3, 1168–1175.
63.
ZhangH., MorganB., PotterB.J., MaL., DellspergerK.C., UngvariZ., ZhangC. (2010) Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress. American Journal of Physiology-Heart and Circulatory Physiology, 299, H985–H994.
64.
Di RenzoL., CarraroA., ValenteR., IacopinoL., ColicaC., De LorenzoA. (2014) Intake of red wine in different meals modulates oxidized LDL level, oxidative and inflammatory gene expression in healthy people: a randomized crossover trial. Oxidative Medicine and Cellular Longevity, 2014, 1–9.
65.
Di RenzoL., MarsellaL.T., CarraroA., ValenteR., GualtieriP., GratteriS., TomasiD., GaiottiF., De LorenzoA. (2015) Changes in LDL oxidative status and oxidative and inflammatory gene expression after red wine intake in healthy people: a randomized trial. Mediators of Inflammation, 2015, 1–13.
66.
KantartzisK., FritscheL., BombrichM., MachannJ., SchickF., StaigerH., KunzI., SchoopR., Lehn-StefanA., HeniM., PeterA., FritscheA., HäringH.U., StefanN. (2018) Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial. Diabetes, Obesity and Metabolism, 20, 1793–1797.
67.
HadleyE.C., LakattaE.G., Morrison-BogoradM., WarnerH.R., HodesR.J. (2005) The future of aging therapies. Cell, 120, 557–567.
68.
SinclairD.A., GuarenteL. (2006) Unlocking the secrets of longevity genes. Scientific American, 294, 48–57.
69.
PallàsM., JunyentF., VerdaguerE., Beas-ZarateC., CaminsA. (2010) Aging control with resveratrol. Drug Discovery today: therapeutic Strategies, 7, 51–56.
70.
IngramD.K., ZhuM., MamczarzJ., ZouS., LaneM.A., RothG.S., deCaboR. (2006) Calorie restriction mimetics: an emerging research field. Aging Cell, 5, 97–108.
UngvariZ., SonntagW.E., De CaboR., BaurJ.A., CsiszarA. (2011) Mitochondrial protection by resveratrol. Exercise and Sport Sciences Review, 39, 128–132.
75.
BrooksC.L., GuW. (2009) How does SIRT1 affect metabolism, senescence and cancer?Nature Reviews Cancer, 9, 123–128.
76.
BorraM.T., SmithB.C., DenuJ.M. (2005) Mechanism of human SIRT1 activation by resveratrol. Journal of Biological Chemistry, 280, 17187–17195.
77.
KaeberleinM., Mc DonaghT., HeltwegB., HixonJ., WestmanE.A., CaldwellS.D., NapperA., CurtisR., DiStefanoP.S., FieldsS., BedalovA., KennedyB.K. (2005) Substrate-specific activation of sirtuins by resveratrol. Journal of Biological Chemistry, 280, 17038–17045.
78.
VaqueroA. (2009) The conserved role of sirtuins in chromatin regulation. The International Journal of Developmental Biology, 53, 303–322.
79.
AnselmiC.V., MaloviniA., RoncaratiR., NovelliV., VillaF., CondorelliG., BellazziR., PucaA.A. (2009) Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Research, 12, 95–104.
80.
LiY., WangW.J., CaoH., LuJ., WuC., HuF.Y., GuoJ., ZhaoL., YangF., ZhangY.X., LiW., ZhengG.Y., CuiH., ChenX., ZhuZ., HeH., DongB., MoX., ZengY., TianX.L. (2009) Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. Human Molecular Genetics, 18, 4897–4904.
81.
FinkelT., DengC.X., MostoslavskyR. (2009) Recent progress in the biology and physiology of sirtuins. Nature, 460, 587–591.
82.
TianY., MaJ., WangW., ZhangL., XuJ., WangK., LiD. (2016) Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Molecular and Cellular Biochemistry, 422, 75–84.
83.
LiX. (2013) SIRT1 and energy metabolism. Acta Biochim Biophys Sin (Shanghai), 45, 51–60.
VaqueroA., SternglanzR., ReinbergD. (2007) NAD+ -dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene, 26, 5505–5520.
86.
KobayashiY., Furukawa-HibiY., ChenC., HorioY., IsobeK., IkedaK., MotoyamaN. (2005) SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. International Journal of Molecular Medicine, 16, 237–243.
CsiszarA. (2011) Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Annals of the New York Academy of Sciences, 1215, 117–122.
89.
PacholecM., BleasdaleJ.E., ChrunykB., CunninghamD., FlynnD., GarofaloR.S., GriffithD., GrifforM., LoulakisP., PabstB., QiuX., StockmanB., ThanabalV., VargheseA., WardJ., WithkaJ., AhnK. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. Journal of Biological Chemistry, 285, 8340–8351.
90.
LagougeM., ArgmannC., Gerhart-HinesZ., MezianeH., LerinC., DaussinF., MessadeqN., MilneJ., LambertP., ElliottP., GenyB., LaaksoM., PuigserverP., AuwerxJ. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127, 1109–1122.
91.
CsiszarA., LabinskyyN., PintoJ.T., BallabhP., ZhangH., LosonczyG., PearsonK., de CaboR., PacherP., ZhangC., UngvariZ. (2009) Resveratrol induces mitochondrial biogenesis in endothelial cells. American Journal of Physiology-Heart and Circulatory Physiology, 297, H13–H20.
92.
CsiszarA., LabinskyyN., JimenezR., PintoJ.T., BallabhP., LosonczyG., PearsonK.J., de CaboR., UngvariZ. (2009) Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1. Mechanisms of Ageing and Development, 130, 518–527.
93.
FerreroM.E., BertelliA.E., FulgenziA., PellegattaF., CorsiM.M., BonfrateM., FerraraF., De CaterinaR., GiovanniniL., BertelliA. (1998) Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. The American Journal of Clinical Nutrition, 68, 1208–1214.
94.
BaurJ.A., PearsonK.J., PriceN.L., JamiesonH.A., LerinC., KalraA., PrabhuV.V., AllardJ.S., Lopez-LluchG., LewisK., PistellP.J., PoosalaS., BeckerK.G., BossO., GwinnD., WangM., RamaswamyS., FishbeinK.W., SpencerR.G., LakattaE.G., Le CouteurD., ShawR.J., NavasP., PuigserverP., IngramD.K., de CaboR., SinclairD.A. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337–342.
95.
PearsonK.J., BaurJ.A., LewisK.N., PeshkinL., PriceN.L., LabinskyyN., SwindellW.R., KamaraD., MinorR.K., PerezE., JamiesonH.A., ZhangY., DunnS.R., SharmaK., PleshkoN., WoollettL.A., CsiszarA., IkenoY., Le CouteurD., ElliottP.J., BeckerK.G., NavasP., IngramD.K., WolfN.S., UngvariZ., SinclairD.A., de CaboR. (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspect of dietary restriction without extending life span. Cell Metabolism, 8, 157–168.
96.
SuH.C., HungL.M., ChenJ.K. (2006) Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. American Journal of Physiology-Endocrinology and Metabolism, 290, E1339–1346.
97.
CsiszarA., UngvariZ., KollerA., EdwardsJ.G., KaleyG. (2004) Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. Physiological Genomics, 17, 21–30.
98.
HoffmannJ., HaendelerJ., AicherA., RössigL., VasaM., ZeiherA.M., DimmelerS. (2001) Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Circulation Research, 89, 709–715.
99.
UngvariZ., LabinskyyN., GupteS., ChanderP.N., EdwardsJ.G., CsiszarA. (2008) Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats. American Journal of Physiology-Heart and Circulatory Physiology, 294, H2121–H2128.
100.
VirgilM., ContestabileA. (2000) Partial neuroprotection of in vivo excitotoxic brain damages by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neuroscience Letters, 281, 123–126.
101.
GaoZ.B., HuG.Y. (2005) Trans-resveratrol, a red wine ingredient, inhibits voltage-activated potassium currents in rat hippocampal neurons. Brain Research, 1056, 68–75.
102.
LiM., WangQ.S., ChenY., WangZ.M., LiuZ., GuoS.M. (2005) Resveratrol inhibits neuronal discharges in rat hippocampal CA1 area. Sheng Li Xue Bao, 57, 355–360.
103.
ShettyA.K. (2011) Promise of resveratrol for easing status epilepticus and epilepsy. Pharmacology & Therapeutics, 131, 269–286.
104.
SunA.Y., ChenY.M., James-KrackeM., WixomP., ChengY. (1997) Ethanol-induced cell death by lipid peroxidation in PC12 cells. Neurochemical Research, 22, 1187–1192.
105.
JangJ.H., SurhY.J. (2003) Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radical Biology and Medicine, 34, 1100–1110.
106.
HanY.S., ZhengW.H., BastianettoS., ChabotJ.G., QuirionR. (2004) Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. British Journal of Pharmacology, 141, 997–1005.
107.
ZhangF., ShiJ.S., ZhouH., WilsonB., HongJ.S., GaoH.M. (2010) Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Molecular Pharmacology, 78, 466–477.
108.
LiuC., ShiZ., FanL., ZhangC., WangK., WangB. (2011) Resveratrol improves neuron protection and functional recovery in rat model of spinal cord injury. Brain Research, 1374, 100–109.
109.
MaherP., DarguschR., BodaiL., GerardP.E., PurcellJ.M., MarshJ.L. (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Human Molecular Genetics, 20, 261–270.
110.
ShindlerK.S., VenturaE., DuttM., ElliottP., FitzgeraldD.C., RostamiA. (2010) Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. Journal of Neuro-Ophthalmology, 30, 328–339.
111.
MarxW., KellyJ.T., MarshallS., CutajarJ., AnnoisB., PipingasA., TierneyA., ItsiopoulosC. (2018) Effect of resveratrol supplementation on cognitive performance and mood in adults: a systematic literature review and meta-analysis of randomized controlled trials. Nutrition Reviews, 76, 432–443.
112.
LombardiG., VanniniS., BlasiF., MarcotullioM.C., DominiciL., VillariniM., CossignaniL., MorettiM. (2015) In vitro safety/protection assessment of resveratrol and pterostilbene in a human hepatoma cell line (HepG2). Natural Product Communications, 10, 1403–1408.
113.
PatelK.R., ScottE., BrownV.A., GescherA.J., StewardW.P., BrownK. (2011) Clinical trials of resveratrol. Annals of the New York Academy of Sciences, 1215, 161–169.
114.
AlmeidaL., Vaz-da-SilvaM., FalcãoA., SoaresE., CostaR., LoureiroA.I., Fernandes-LopesC., RochaJ.F., NunesT., WrightL., Soares-da-SilvaP. (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Molecular Nutrition & Food Research, 53, S7–S15.
115.
BoocockD.J., FaustG.E., PatelK.R., SchinasA.M., BrownV.A., DucharmeM.P., BoothT.D., CrowellJ.A., PerloffM., GescherA.J., StewardW.P., BrennerD.E. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology, Biomarkers & Prevention, 16, 1246–1252.
116.
BrownV.A., PatelK.R., ViskadurakiM., CrowellJ.A., PerloffM., BoothT.B., VasilininG., SenA., SchinasA.M., PiccirilliG., BrownK., StewardW.P., GescherA.J., BrennerD.E. (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Research, 70, 9003–9011.
117.
La PorteC., VoducN., ZhangG., SeguinI., TardiffD., SinghalN., CameronD.W. (2010) Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clinical Pharmacokinetics, 49, 449–454.
118.
ShuklaY., SinghR. (2011) Resveratrol and cellular mechanisms of cancer prevention. Annals of the New York Academy of Sciences, 1215, 1–8.
119.
TyihákE., Király-VéghelyZ., MóriczA.M. (2011) Multiple beneficial effects of resveratrol and their chemical-biochemical basis. Natural Product Communications, 6, 631–638.
120.
CanturkZ., DikmenM., ArtaganO., OzardaM.G., OzturkN. (2016) Cytotoxic effects of resveratrol, rutin and rosmarinic acid on ARH–77 human (multiple myeloma) cell line. Natural Product Communications, 11, 1441–1444.
121.
PyoK-H, LeeY-W, LeeS-H, XinC-F, ShinJ-H, ShinE.H. (2017) Preventive effects of resveratrol-enriched extract of peanut sprout on bacteria-and estradiol-induced prostatitis in mice. Natural Product Communications, 12, 73–78.
122.
SintuyanonN., PhoolcharoenW., PavasantP., SooamponS. (2017) Resveratrol demonstrated higher antiproliferative and antiangiogenic efficacy compared with oxyresveratrol on head and neck squamous cell carcinoma cell lines. Natural Product Communications, 12, 1781–1784.
123.
DybkowskaE., SadowskaA., ŚwiderskiF., RakowskaR., WysockaK. (2018) The occurrence of resveratrol in foodstuffs and its potential for supporting cancer prevention and treatment. A review. Roczniki Państwowego Zakładu Higieny, 69, 5–14.
124.
KudoT., NarisawaT., AboS. (1980) Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann, 71, 260–264.
125.
JangM., CaiL., UdeaniG.O., SlowingK.V., ThomasC.F., BeecherC.W., FongH.H., FarnsworthN.R., KinghornA.D., MehtaR.G., MoonR.C., PezzutoJ.M. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218–220.
126.
GarvinS., OllingerK., DabrosinC. (2006) Resveratrol induces apoptosis and inhibit angiogenesis in human breast cancer xenografts in vivo.Cancer Letters, 231, 113–122.
127.
KalraN., RoyP., PrasadS., ShuklaY. (2008) Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sciences, 82, 348–358.
128.
KunduJ.K., SurhY.J. (2004) Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutation Research, 555, 65–80.
129.
LiaoD., JohnsonR.S. (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer and Metastasis Reviews, 26, 281–290.
130.
López-LázaroM. (2006) Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. Cancer Epidemiology, Biomarkers & Prevention, 15, 2332–2335.
131.
HickeyM.M., SimonM.C. (2006) Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Current Topics in Developmental Biology, 76, 217–257.
132.
NorthS., MoennerM., BikfalviA. (2005) Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Letters, 218, 1–14.
133.
GatouillatG., BalasseE., Joseph-PietrasD., MorjaniH., MadouletC. (2010) Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. Journal of Cellular Biochemistry, 110, 893–902.
134.
ChengT.M., ChinY.T., HoY., ChenY.R., YangY.N., YangY.C., ShihY.J., LinT.I., LinH.Y., DavisP.J. (2018) Resveratrol induces sumoylated COX-2-dependent anti-proliferation in human prostate cancer LNCaP cells. Food and Chemical Toxicology, 112, 67–75.
135.
GuptaS.C., KannappanR., ReuterS., KimJ.H., AggarwalB.B. (2011) Chemosensitization of tumors by resveratrol. Annals of the New York Academy of Sciences, 1215, 150–160.
BhartiA.C., ShishodiaS., ReubenJ.M., WeberD., AlexanianR., Raj-VadhanS., EstrovZ., TalpazM., AggarwalB.B. (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood, 103, 3175–3184.
138.
NiedzwieckiA., RoomiM.W., KalinovskyT., RathM. (2016) Anticancer efficacy of polyphenols and their combinations. Nutrients, 8, 1–17.
139.
AsensiM., MedinaI., OrtegaA., CarreteroJ., BañoM.C., ObradorE., EstrelaJ.M. (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biology and Medicine, 33, 387–398.
140.
CarterL.G., D'OrazioJ.A., PearsonK.J. (2014) Resveratrol and cancer: focus on in vivo evidence. Endocrine-Related Cancer, 21, R209–R225.
141.
HaoJ., TuckA.R., SjödinM.O.D., LindbergJ., SandA., NiklassonB., ArgyrakiM., HovattaO., DamdimopoulouP. (2018) Resveratrol supports and alpha-naphthoflavone disrupts growth of human ovarian follicles in an in vitro tissue culture model. Toxicology and Applied Pharmacology, 338, 73–82.
